CR10493A - Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata - Google Patents

Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata

Info

Publication number
CR10493A
CR10493A CR10493A CR10493A CR10493A CR 10493 A CR10493 A CR 10493A CR 10493 A CR10493 A CR 10493A CR 10493 A CR10493 A CR 10493A CR 10493 A CR10493 A CR 10493A
Authority
CR
Costa Rica
Prior art keywords
igf
assistants
growth factor
prostate cancer
cancer treatment
Prior art date
Application number
CR10493A
Other languages
English (en)
Inventor
Meera Agarkhed
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of CR10493A publication Critical patent/CR10493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

En una modalidad, la presente invencion proporciona una formulacion liofilizada que comprende un anticuerpo anti-EGFR, de preferencia cetuximab; acido lactobionico; y una solucion reguladora, de preferencia histidina. En una modalidad preferida, la presente invencion proporciona una formulacion liofilizada estable que comprende aproximadamente 50 mg/mL a aproximadamente 140 mg/mL de ERBITUX, aproximadamente acido lactobionico 0.125%, aproximadamente solucion reguladora de histidina 25mM a un pH de aproximadamente 6.0, aproximadamente Tween 80 0.005%, y aproximadamente glicina 1.875%.
CR10493A 2006-06-14 2008-12-11 Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata CR10493A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14

Publications (1)

Publication Number Publication Date
CR10493A true CR10493A (es) 2009-02-26

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10493A CR10493A (es) 2006-06-14 2008-12-11 Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata

Country Status (18)

Country Link
US (1) US20100158925A1 (es)
EP (1) EP2029163A4 (es)
JP (1) JP2009540015A (es)
KR (1) KR20090021298A (es)
CN (1) CN101466404A (es)
AU (1) AU2007260769A1 (es)
BR (1) BRPI0713421A2 (es)
CA (1) CA2654794A1 (es)
CR (1) CR10493A (es)
EA (1) EA200870538A1 (es)
EC (1) ECSP088962A (es)
IL (1) IL195794A0 (es)
MA (1) MA30515B1 (es)
MX (1) MX2008015852A (es)
NO (1) NO20085131L (es)
TN (1) TNSN08511A1 (es)
WO (1) WO2007147001A2 (es)
ZA (1) ZA200810456B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2501408B1 (en) * 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
JP6282745B2 (ja) * 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
JP6214790B2 (ja) * 2014-09-16 2017-10-18 イース チャーム リミテッド 抗ｅｇｆｒ抗体および同抗体の使用法
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US10736893B2 (en) 2015-11-06 2020-08-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
AU2017386888B2 (en) * 2016-12-28 2024-08-08 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
SG11202011538RA (en) * 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP2022535924A (ja) * 2019-06-06 2022-08-10 ジャナックス セラピューティクス，インク． 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
EP4631977A3 (en) 2020-08-11 2025-12-10 Janux Therapeutics, Inc. Cleavable linker compositions and methods
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US20240383968A1 (en) * 2020-12-11 2024-11-21 Boehringer Ingelheim International Gmbh Formulation for multi-purpose application
JP2024536275A (ja) * 2021-10-03 2024-10-04 システィミューン， インク． がんを治療する方法及びその医薬組成物
CN119855620A (zh) * 2022-09-16 2025-04-18 国立研究开发法人量子科学技术研究开发机构 放射性医药组合物的中间体的制造方法、放射性医药组合物的中间体的纯化用试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
CN101495136A (zh) * 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品

Also Published As

Publication number Publication date
ZA200810456B (en) 2009-12-30
CA2654794A1 (en) 2007-12-21
AU2007260769A1 (en) 2007-12-21
WO2007147001A3 (en) 2008-07-10
BRPI0713421A2 (pt) 2012-03-13
NO20085131L (no) 2009-03-13
MA30515B1 (fr) 2009-06-01
WO2007147001A2 (en) 2007-12-21
KR20090021298A (ko) 2009-03-02
EP2029163A4 (en) 2010-08-11
EA200870538A1 (ru) 2009-04-28
IL195794A0 (en) 2011-08-01
US20100158925A1 (en) 2010-06-24
TNSN08511A1 (en) 2010-04-14
JP2009540015A (ja) 2009-11-19
EP2029163A2 (en) 2009-03-04
ECSP088962A (es) 2009-01-30
CN101466404A (zh) 2009-06-24
MX2008015852A (es) 2009-02-23

Similar Documents

Publication Publication Date Title
CR10493A (es) Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata
AR063150A1 (es) Formulaciones estables
AR111497A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos
SV2006002182A (es) Nuevos anticuerpos anti-igf-1r y sus usos ref. 348207/d22514 mip
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
AR080158A1 (es) Anticuerpos contra el receptor de la muerte 5
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
NZ719036A (en) Anti-pdl1 antibody formulations
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
TN2009000382A1 (en) Stable antibody formulations
AR085955A1 (es) Proteinas de union al antigeno
TW200616661A (en) HER2 antibody composition
CL2008001675A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-factorde crecimiento endotelial vascular (vegf); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion;antogonista de vegf que comprende el dab; composicion que comprende antogonista;y uso del antagonista para preparar un medicamento.
GT200600324A (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
BR112014016723A2 (pt) método para o tratamento de câncer de mama
NZ595755A (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)